Guggenheim Capital LLC Invests $807,000 in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Guggenheim Capital LLC bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 31,389 shares of the company's stock, valued at approximately $807,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. XTX Topco Ltd lifted its position in IDEAYA Biosciences by 64.3% in the 4th quarter. XTX Topco Ltd now owns 12,679 shares of the company's stock valued at $326,000 after purchasing an additional 4,960 shares during the last quarter. Mariner LLC boosted its stake in IDEAYA Biosciences by 9.8% in the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares during the period. Barclays PLC lifted its stake in IDEAYA Biosciences by 9.7% in the 4th quarter. Barclays PLC now owns 198,756 shares of the company's stock worth $5,108,000 after acquiring an additional 17,586 shares in the last quarter. Raymond James Financial Inc. purchased a new position in IDEAYA Biosciences during the fourth quarter valued at approximately $431,000. Finally, Renaissance Technologies LLC increased its holdings in IDEAYA Biosciences by 66.9% in the fourth quarter. Renaissance Technologies LLC now owns 284,267 shares of the company's stock worth $7,306,000 after buying an additional 113,902 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens reaffirmed an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Stock Up 0.9 %

NASDAQ:IDYA traded up $0.18 during mid-day trading on Tuesday, hitting $19.93. 96,948 shares of the stock traded hands, compared to its average volume of 956,490. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The company has a market cap of $1.74 billion, a PE ratio of -6.03 and a beta of 0.51. The business's 50-day moving average price is $17.98 and its 200 day moving average price is $23.29.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. Analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.